Table 1.

Summary of the randomized controlled trials (RCTs) included in this meta-analysis

Author	Year	Phase of the trial	Duration of therapy	Intervention arm-1	Intervention arm-2	Intervention arm-3	Intervention arm-4	Control arm
Kremer JM et al. study 1 [18]	2012	Phase IIb	24-weeks	Tofacitinib 3-mg BID + Methotrexate (N = 68)	Tofacitinib 5-mg BID + Methotrexate (N = 71)	Tofacitinib 10-mg BID + Methotrexate (N = 74)	Tofacitinib 15-mg BID + Methotrexate (N = 75)	Placebo + Methotrexate (N = 69)
Tanaka Y et al. [19]	2011	Phase II	12-weeks	Tofacitinib 3-mg BID + Methotrexate (28)	Tofacitinib 5-mg BID + Methotrexate (N = 28)	Tofacitinib 10-mg BID + Methotrexate (N = 28)	..	Placebo + Methotrexate (N = 28)
Fleischmann R et al. study 1 [16]	2012	Phase IIb	24-weeks	Tofacitinib 3-mg BID (N = 51)	Tofacitinib 5-mg BID (N = 49)	Tofacitinib 10-mg BID (N = 61)	Tofacitinib 15-mg BID (N = 57)	Placebo (N = 59)
Fleischmann R et al. study 2 [11]	2012	Phase III	6-months	..	Tofacitinib 5-mg BID (N = 243)	Tofacitinib 10-mg BID (N = 245)	..	Placebo (N = 122)
Kremer JM et al. study 2 [17]	2009	Phase IIa	12-weeks	.	Tofacitinib 5-mg BID (N = 61)	..	Tofacitinib 15-mg BID (N = 69)	Placebo (N = 65)
Burmester GR et al. [10]	2013	Phase III	6-months	…	Tofacitinib 5-mg BID + Methotrexate (N = 133)	Tofacitinib 10-mg BID + Methotrexate (N = 134)	..	Placebo + Methotrexate (N = 132)
van der Heijde D et al. [12]	2013	Phase III	24-month	..	Tofacitinib 5-mg BID + Methotrexate (N = 321)	Tofacitinib 10-mg BID + Methotrexate (N = 316)	..	Placebo + Methotrexate (N = 160)
van Vollenhoven RF et al. [13]	2012	Phase III	12-month	..	Tofacitinib 5-mg BID + Methotrexate (N = 204)	Tofacitinib 10-mg BID + Methotrexate (N = 201)	..	Placebo + Methotrexate (N = 108)

N = Sample size.